Literature DB >> 8791950

Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.

B H Jaup1, A Norrby.   

Abstract

BACKGROUND: One-week triple therapy consisting of omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. is an effective therapy for H. pylori infection with a cure rate of 93%. We therefore compared two similar 1-week regimens consisting of a lansoprazole, clarithromycin and either metronidazole or tetracycline in a prospective study.
METHODS: Two cohorts, each of 60 patients suffering from H. pylori infection associated with peptic ulcer disease or ulcer-like dyspepsia, were treated for 1 week with either lansoprazole 30 mg b.d., clarithromycin 250 mg b.d. and either metronidazole 400 mg b.d. (cohort A, n = 60) or tetracycline 300 mg b.d. (cohort B, n = 60). Four weeks after treatment, cure of H. pylori infection was evaluated by endoscopy using rapid urease testing together with histology.
RESULTS: In cohort A, 55 patients out of 60 showed cure of H. pylori infection (92%); the treatment was well tolerated, but three patients suffered from side-effects. In cohort B, which was free of metronidazole, 50 out of 60 patients showed cure of H. pylori infection (83%); two patients reported side-effects. The differences between the two cohorts were not statistically significant.
CONCLUSION: Triple therapy for 1 week with lansoprazole as the antisecretory agent seems to be as effective as is reported for omeprazole-based regimens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791950     DOI: 10.1111/j.0953-0673.1996.00275.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

Review 1.  Helicobacter pylori.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

Review 2.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

3.  Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.

Authors:  D J Kearney; A Brousal
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.